Table 2.
Resting cerebral blood flow before and after treatment with a partial dopamine agonist in primary and explorative regions of interest
| Regions of interest | Mean CBF (mL/100 g/min ± s.d.) | Group × time interaction | Post hoc tests | Main effect group | |||||
|---|---|---|---|---|---|---|---|---|---|
| N Baseline/N 6weeks | Baseline | 6 weeks | |||||||
| FEP | HC | FEP | HC | FEP | HC | ||||
| Thalamus (%change ± s.d.) | 49/29 | 50/49 | 60.3 ± 14.6 | 61.5 ± 15.0 | 61.1 ± 14.8 (3.0 ± 20.9%) | 56.9 ± 14.7 (−6.4 ±2 0.7%) | p = 0.040a | FEP = HC baseline: p = 0.89 FEP > HC 6 weeks: p = 0.14 |
– |
| Whole striatumb (%change ± s.d.) | 46/29 | 48/47 | 41.3 ± 7.8 | 41.8 ± 9.4 | 43.1 ± 8.5 (4.8 ± 18.4%) | 40.1 ± 6.9 (−0.7±24.0%) | p = 0.020a | FEP = HC baseline: p = 0.92 FEP > HC 6 weeks: p = 0.006 |
– |
| Putamenb (%change ± s.d.) | 46/29 | 48/47 | 42.4 ± 8.8 | 43.8 ± 10.9 | 45.0 ± 8.9 (7.8 ± 22.4%) | 41.6 ± 7.7 (−2.5 ± 22.6%) | p = 0.004 | FEP = HC baseline: p = 0.64 FEP > HC 6 weeks: p = 0.005 |
– |
| Nucleus accumbensb (%change ± s.d.) | 46/29 | 48/47 | 36.2 ± 9.0 | 37.5 ± 12.3 | 40.0 ± 10.2 (16.0 ± 32.9%) | 35.7 ± 8.8 (2.1 ± 28.2%) | p = 0.01 | FEP = HC baseline: p = 0.51 FEP > HC 6 weeks: p = 0.04 |
– |
| Caudateb (%change ± s.d.) | 46/29 | 48/47 | 43.9 ± 9.6 | 43.6 ± 9.9 | 45.4 ± 10.5 (4.5 ± 21.1%) | 42.8 ± 8.3 (2.2 ± 29.6%) | p = 0.46 | – | p = 0.26 |
| Hippocampus (%change ± s.d.) | 49/29 | 50/49 | 30.7 ± 7.5 | 32.1 ± 9.8 | 31.6 ± 7.5 (7.8 ± 22.4%) | 29.8 ± 6.5 (−2.5 ± 22.6%) | p = 0.13 | – | p = 0.99 |
| Frontal lobe (%change ± s.d.) | 49/29 | 50/49 | 56.7 ± 57.2 | 57.2 ± 11.4 | 55.7 ± 9.9 (−1.3 ± 14.4%) | 54.8 ± 10.4 (−2.6 ± 18.3%) | p = 0.70 | – | p = 0.82 |
| Global rCBFc (%change ± s.d.) | 49/29 | 50/49 | 50.7 ± 8.4 | 51.4 ± 9.3 | 49.6 ± 8.1 (−2.1 ± 13.2%) | 48.7 ± 8.3 (−3.7 ± 17.4%) | p = 0.42 | – | p = 0.95 |
Abbreviations: FEP, First-episode psychosis patients; HC, Healthy controls; rCBF, resting cerebral blood flow; s.d., standard deviation.
Table 2 shows resting cerebral blood flow (rCBF) in regions of interest in first-episode patients and healthy controls. Statistical analyses are adjusted for global rCBF, smoking status, age, and sex.
The significance level was set to p < 0.025 due to two primary regions of interest.
Striatal rCBF could not be calculated in three patients due to poor anatomical segmentation of striatum.
Analyses of global rCBF are corrected for age and sex. The percent change of rCBF was calculated as: [(baseline-6 weeks)/baseline] × 100%.